AJMC articleshttps://www.ajmc.com/newsAJMC articles© 2026 MJH Life Sciences™ and AJMC. All rights reserved.Tue, 21 Jul 2026 06:47:51 +00005en-us14447https://www.ajmc.com/newshttps://www.ajmc.com/logo.webphttps://www.ajmc.com/view/case-studies-focus-on-glofitamab-as-bridge-to-car-t-in-mclhttps://www.ajmc.com/view/case-studies-focus-on-glofitamab-as-bridge-to-car-t-in-mcl<![CDATA[Case series suggests glofitamab bridges relapsed mantle cell lymphoma to CAR T, with strong responses and mostly low-grade CRS.]]>Mon, 20 Jul 2026 23:58:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/adding-epcoritamab-to-r2-in-r-r-follicular-lymphoma-meets-cost-effectiveness-testshttps://www.ajmc.com/view/adding-epcoritamab-to-r2-in-r-r-follicular-lymphoma-meets-cost-effectiveness-tests<![CDATA[New data suggest epcoritamab plus R2 may win insurer coverage, delivering major QALY gains at approximately $68,000 and delaying costly progression.]]>Mon, 20 Jul 2026 22:52:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/access-barriers-not-science-slow-retina-care-paul-hahn-mdhttps://www.ajmc.com/view/access-barriers-not-science-slow-retina-care-paul-hahn-md<![CDATA[Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next.]]>Mon, 20 Jul 2026 21:10:42 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/crc-treatment-delays-linked-to-higher-metastasis-risk-supporting-pathway-specific-benchmarkshttps://www.ajmc.com/view/crc-treatment-delays-linked-to-higher-metastasis-risk-supporting-pathway-specific-benchmarks<![CDATA[CRC treatment delays were linked to higher metastatic risk, but meaningful thresholds varied by treatment pathway, supporting tailored benchmarks. ]]>Mon, 20 Jul 2026 21:03:47 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/early-onset-ckd-mortality-declines-globally-as-incidence-continues-to-risehttps://www.ajmc.com/view/early-onset-ckd-mortality-declines-globally-as-incidence-continues-to-rise<![CDATA[Global early-onset CKD mortality declined from 1990 to 2021, but incidence rose, highlighting persistent disparities and prevention needs.]]>Mon, 20 Jul 2026 18:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/active-us-drug-shortages-rise-for-third-straight-quarterhttps://www.ajmc.com/view/active-us-drug-shortages-rise-for-third-straight-quarter<![CDATA[US drug shortages rose to 227 in Q2 2026, led by a severe ifosfamide shortage.]]>Mon, 20 Jul 2026 17:01:01 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/medicaid-mfn-pricing-could-save-8-6-billionhttps://www.ajmc.com/view/medicaid-mfn-pricing-could-save-8-6-billion<![CDATA[Existing rebates and manufacturers' gaming risk may limit these gains.]]>Mon, 20 Jul 2026 16:45:38 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/tonmya-cyclobenzaprine-hcl-sublingual-tablets-an-innovative-approach-to-fibromyalgia-managementhttps://www.ajmc.com/view/tonmya-cyclobenzaprine-hcl-sublingual-tablets-an-innovative-approach-to-fibromyalgia-management<![CDATA[This Clinical Brief was sponsored by Tonix Medicines, Inc.]]>Mon, 20 Jul 2026 15:05:06 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/the-road-ahead-personalized-therapy-combination-approaches-and-key-takeaways-in-extrapulmonary-neuroendocrine-carcinomahttps://www.ajmc.com/view/the-road-ahead-personalized-therapy-combination-approaches-and-key-takeaways-in-extrapulmonary-neuroendocrine-carcinoma<![CDATA[Experts outline evolving EP-NEC care: smarter combo therapies, DLL3 targets, precise pathology, and why early clinical trials matter.]]>Mon, 20 Jul 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/prior-cancer-history-predicts-second-cancers-in-polycythemia-vera-essential-thrombocythemiahttps://www.ajmc.com/view/prior-cancer-history-predicts-second-cancers-in-polycythemia-vera-essential-thrombocythemia<![CDATA[Patients with a history of nonmelanoma skin cancer had a 548% greater likelihood to develop another skin cancer vs those with no cancer history.]]>Sun, 19 Jul 2026 15:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/hepatitis-prevention-programs-improve-liver-outcomes-but-gaps-in-screening-care-remainhttps://www.ajmc.com/view/hepatitis-prevention-programs-improve-liver-outcomes-but-gaps-in-screening-care-remain<![CDATA[Hepatitis B and C prevention programs improve detection, treatment, and liver outcomes, but screening, care access, and implementation gaps remain.]]>Sun, 19 Jul 2026 14:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/navigating-myeloma-s-crowded-treatment-frontier-swarup-kumar-mdhttps://www.ajmc.com/view/navigating-myeloma-s-crowded-treatment-frontier-swarup-kumar-md<![CDATA[Swarup Kumar, MD, also details treating incarcerated patients with bispecifics and pursuing cure-focused therapy sequencing in myeloma.]]>Sun, 19 Jul 2026 13:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/clinical-trials-leave-many-all-patients-behind-emily-k-curran-mdhttps://www.ajmc.com/view/clinical-trials-leave-many-all-patients-behind-emily-k-curran-md<![CDATA[Emily Curran, MD, University of Cincinnati, calls for decentralized trials and stronger community-academic ties to widen ALL patient access.]]>Sat, 18 Jul 2026 14:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/ai-phenotyping-links-cardiovascular-kidney-disease-to-rapid-mash-progression-higher-costshttps://www.ajmc.com/view/ai-phenotyping-links-cardiovascular-kidney-disease-to-rapid-mash-progression-higher-costs<![CDATA[AI phenotyping identified cardiovascular and kidney disease as key predictors of rapid fibrosis progression, complications, and higher costs in MASH.]]>Sat, 18 Jul 2026 14:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/deep-learning-model-matches-expert-agreement-in-sleep-arousal-scoringhttps://www.ajmc.com/view/deep-learning-model-matches-expert-agreement-in-sleep-arousal-scoring<![CDATA[The AI model matched or beat expert agreement on sleep arousal scoring, outperforming interscorer reliability across 10 scorers in an independent dataset.]]>Fri, 17 Jul 2026 19:00:38 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/5-things-to-know-about-dry-eye-during-awareness-monthhttps://www.ajmc.com/view/5-things-to-know-about-dry-eye-during-awareness-month<![CDATA[Dry eye disease primarily causes stinging in the eye and blurry vision, which can affect quality of life.]]>Fri, 17 Jul 2026 18:56:01 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/hereditary-hemochromatosis-a-preventable-burden-hidden-in-plain-sighthttps://www.ajmc.com/view/hereditary-hemochromatosis-a-preventable-burden-hidden-in-plain-sight<![CDATA[A common, underdiagnosed genetic disorder, hereditary hemochromatosis is costly when caught late and simple to treat when caught early.]]>Fri, 17 Jul 2026 16:52:06 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/health-equity-access-weekly-roundup-july-17-2026https://www.ajmc.com/view/health-equity-access-weekly-roundup-july-17-2026<![CDATA[Hospital-at-home meets inpatient safety, PBM insulin settlement lowers costs, SNAP narrows screening gaps, and execs warn innovation outpaces reimbursement.]]>Fri, 17 Jul 2026 16:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/before-the-first-bispecific-dose-community-practices-need-a-playbookhttps://www.ajmc.com/view/before-the-first-bispecific-dose-community-practices-need-a-playbook<![CDATA[Designated teams, standardized SOPs, and scalable workflows are essential before a community practice's first bispecific dose. ]]>Fri, 17 Jul 2026 15:15:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/expanding-the-role-of-pcsk9-sglt2-inhibitors-in-cardiovascular-prevention-deepak-bhatt-md-mph-mbahttps://www.ajmc.com/view/expanding-the-role-of-pcsk9-sglt2-inhibitors-in-cardiovascular-prevention-deepak-bhatt-md-mph-mba<![CDATA[Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 and SGLT2 inhibitors are used.]]>Fri, 17 Jul 2026 15:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/stem-cell-transplant-outperforms-dmts-in-drug-resistant-relapsing-mshttps://www.ajmc.com/view/stem-cell-transplant-outperforms-dmts-in-drug-resistant-relapsing-ms<![CDATA[AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains.]]>Fri, 17 Jul 2026 13:32:52 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/ajmc-in-the-press-july-17-2026https://www.ajmc.com/view/ajmc-in-the-press-july-17-2026<![CDATA[Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.]]>Fri, 17 Jul 2026 13:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/early-data-support-inca033989-in-calr-mutant-myelofibrosis-claire-harrison-mdhttps://www.ajmc.com/view/early-data-support-inca033989-in-calr-mutant-myelofibrosis-claire-harrison-md<![CDATA[INCA033989 showed responses across type 1 and type 2 mutant calreticulin-positive myelofibrosis, with phase 3 studies underway.]]>Fri, 17 Jul 2026 13:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/synchronize-1-through-a-hepatologist-s-lens-liver-fat-reduction-visceral-fat-and-what-comes-nexthttps://www.ajmc.com/view/synchronize-1-through-a-hepatologist-s-lens-liver-fat-reduction-visceral-fat-and-what-comes-next<![CDATA[Gunn described her reaction to the SYNCHRONIZE-1 liver fat reduction data as genuinely compelling from a hepatology perspective, noting a reduction of up to 63% represents a level of hepatic fat clearance that could meaningfully transform the disease trajectory for patients, with the data also demonstrating reductions in non-invasive markers of fibrosis such as ELF and Pro-C3, adding further weight to the possibility that this combination could address not just fat accumulation but the fibrotic progression that drives the most serious liver-related morbidity.]]>Fri, 17 Jul 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/hr-positive-breast-cancer-growing-demand-for-ctdna-testing-and-implementation-challengeshttps://www.ajmc.com/view/hr-positive-breast-cancer-growing-demand-for-ctdna-testing-and-implementation-challenges<![CDATA[This segment explores increasing interest from both patients and clinicians in ctDNA testing and emerging targeted therapies in hormone receptor–positive, HER2-negative metastatic breast cancer.]]>Fri, 17 Jul 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/navigating-treatment-sequencing-and-defining-failure-in-moderate-to-severe-atopic-dermatitishttps://www.ajmc.com/view/navigating-treatment-sequencing-and-defining-failure-in-moderate-to-severe-atopic-dermatitis<![CDATA[Angela Lamb discussed how the lack of robust head-to-head comparative data across interleukin-targeting biologics contributes to biologic cycling, noting that without clear guidance on which agent best matches a given patient's immunologic drivers, clinician decision-making often relies on phenotype and clinical experience rather than predictive data.]]>Fri, 17 Jul 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/beyond-glp-1-the-biological-case-for-dual-incretin-therapy-in-mashhttps://www.ajmc.com/view/beyond-glp-1-the-biological-case-for-dual-incretin-therapy-in-mash<![CDATA[Gunn explained the scientific rationale for combining GLP-1 and glucagon receptor agonism in the context of MASH, noting that the liver contains glucagon receptors, making the combination a compelling strategy for achieving more direct hepatic targeting than GLP-1 receptor agonism alone can provide.]]>Fri, 17 Jul 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/hr-positive-breast-cancer-patient-perspectives-on-ctdna-guided-treatment-decisionshttps://www.ajmc.com/view/hr-positive-breast-cancer-patient-perspectives-on-ctdna-guided-treatment-decisions<![CDATA[This segment explores patient perspectives and acceptance of biomarker-driven treatment strategies in hormone receptor–positive, HER2-negative metastatic breast cancer.]]>Fri, 17 Jul 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/voice-biomarkers-show-promise-for-asthma-copd-exacerbation-detectionhttps://www.ajmc.com/view/voice-biomarkers-show-promise-for-asthma-copd-exacerbation-detection<![CDATA[Voice changes may help detect asthma and COPD exacerbations early, supporting future remote disease monitoring. ]]>Thu, 16 Jul 2026 19:29:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/rethinking-cardiometabolic-risk-deepak-bhatt-md-mph-mbahttps://www.ajmc.com/view/rethinking-cardiometabolic-risk-deepak-bhatt-md-mph-mba<![CDATA[Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease.]]>Thu, 16 Jul 2026 17:30:42 GMTAJMCusAJMC Articles